Forte Biosciences, Inc. (FBRX)Healthcare | Biotechnology | Dallas, United States | NasdaqCM
32.84 USD
-1.59
(-4.618%) ⇩
(April 21, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | April 18, 2026, 10:22 p.m. EDT
Forte Biosciences is positioned as a high-beta biotech play on near-term data readouts, characterized by extremely skewed options positioning that bets on a rapid move higher in the next few weeks while the equity value is supported by a $150M capital raise. Despite the 'Strong Buy' analyst consensus and significant financial dilution from the stock offering hurting long-term purity, the technicals and options flow provide a strong bullish edge for a multi-week run targeting analyst price targets in the $60-75 range. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.089553 |
| AutoETS | 0.089556 |
| MSTL | 0.099182 |
| AutoTheta | 0.410213 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 48% |
| H-stat | 5.30 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.480 |
| Excess Kurtosis | -0.65 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 643,519,616 |
| Forward P/E | -7.86 |
| Beta | 3.20 |
| Website | https://www.fortebiorx.com |
As of April 18, 2026, 10:22 p.m. EDT: Options activity for the April 17 expiration reveals a massive disconnect implying a 'short squeeze' setup for price convergence. Over 460 contracts of ATM (-$35) puts have been written, while volume is low (1), indicating speculators are aggressively betting on higher prices with minimal cost (writing spreads). Conversely, call volume is negligible (2 lots), leading to extremely understated implied volatilities (13-15% vs historical averages). For the May 15 and August expirations, callBuying has modestly increased, particularly at the $40 strike, suggesting 3-month horizons require a higher target price, but the overwhelming near-term Theta decay on the put side signals a strong consensus for a medium-to-long-term advance within the next month.
| Attribute | Value |
|---|---|
| 52 Week Change | 4.428099 |
| Address1 | 3,060 Pegasus Park Drive |
| Address2 | Building 6 |
| All Time High | 6,732.375 |
| All Time Low | 4.11 |
| Ask | 42.45 |
| Ask Size | 2 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 588,890 |
| Average Daily Volume3 Month | 290,603 |
| Average Volume | 290,603 |
| Average Volume10Days | 588,890 |
| Beta | 3.199 |
| Bid | 24.45 |
| Bid Size | 2 |
| Book Value | 3.421 |
| City | Dallas |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 32.84 |
| Current Ratio | 3.884 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 34.82 |
| Day Low | 32.745 |
| Display Name | Forte Biosciences |
| Dividend Date | 1,592,265,600 |
| Earnings Timestamp End | 1,755,518,400 |
| Earnings Timestamp Start | 1,754,996,340 |
| Ebitda | -70,593,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -7.641 |
| Enterprise Value | 539,393,408 |
| Eps Current Year | -4.26 |
| Eps Forward | -4.178 |
| Eps Trailing Twelve Months | -4.71 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 28.775 |
| Fifty Day Average Change | 4.0650005 |
| Fifty Day Average Change Percent | 0.14126848 |
| Fifty Two Week Change Percent | 442.8099 |
| Fifty Two Week High | 35.8 |
| Fifty Two Week High Change | -2.959999 |
| Fifty Two Week High Change Percent | -0.082681544 |
| Fifty Two Week Low | 4.9 |
| Fifty Two Week Low Change | 27.94 |
| Fifty Two Week Low Change Percent | 5.7020407 |
| Fifty Two Week Range | 4.9 - 35.8 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,492,090,200,000 |
| Float Shares | 17,321,811 |
| Forward Eps | -4.178 |
| Forward P E | -7.8602204 |
| Free Cashflow | -26,935,624 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 19 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.02358 |
| Held Percent Institutions | 0.67168 |
| Implied Shares Outstanding | 19,595,604 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,724,803,200 |
| Last Split Factor | 1:25 |
| Long Business Summary | Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as graft-vs-host disease, vitiligo, and alopecia areata, as well as for celiac disease and non-segmental vitiligo. Forte Biosciences, Inc. is headquartered in Dallas, Texas. |
| Long Name | Forte Biosciences, Inc. |
| Market | us_market |
| Market Cap | 643,519,616 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_594626683 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -69,375,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 646,067,063 |
| Number Of Analyst Opinions | 4 |
| Open | 34.5 |
| Operating Cashflow | -50,882,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 310 618 6994 |
| Previous Close | 34.43 |
| Price Eps Current Year | -7.70892 |
| Price Hint | 2 |
| Price To Book | 9.599532 |
| Profit Margins | 0.0 |
| Quick Ratio | 3.748 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | -1.59 |
| Regular Market Change Percent | -4.61807 |
| Regular Market Day High | 34.82 |
| Regular Market Day Low | 32.745 |
| Regular Market Day Range | 32.745 - 34.82 |
| Regular Market Open | 34.5 |
| Regular Market Previous Close | 34.43 |
| Regular Market Price | 32.84 |
| Regular Market Time | 1,776,801,600 |
| Regular Market Volume | 183,902 |
| Return On Assets | -0.6119 |
| Return On Equity | -1.22278 |
| Sand P52 Week Change | 0.3140242 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 19,595,604 |
| Shares Percent Shares Out | 0.0643 |
| Shares Short | 892,176 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 712,069 |
| Short Name | Forte Biosciences, Inc. |
| Short Percent Of Float | 0.0747 |
| Short Ratio | 3.93 |
| Source Interval | 15 |
| State | TX |
| Symbol | FBRX |
| Target High Price | 75.0 |
| Target Low Price | 54.0 |
| Target Mean Price | 63.75 |
| Target Median Price | 63.0 |
| Total Cash | 76,957,000 |
| Total Cash Per Share | 4.1 |
| Total Debt | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -4.71 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 20.009375 |
| Two Hundred Day Average Change | 12.830626 |
| Two Hundred Day Average Change Percent | 0.6412307 |
| Type Disp | Equity |
| Volume | 183,902 |
| Website | https://www.fortebiorx.com |
| Zip | 75,247 |